WO2007147185A1 - Procédé pour produire une surface de glace pour des pistes de patinage - Google Patents

Procédé pour produire une surface de glace pour des pistes de patinage Download PDF

Info

Publication number
WO2007147185A1
WO2007147185A1 PCT/AT2007/000298 AT2007000298W WO2007147185A1 WO 2007147185 A1 WO2007147185 A1 WO 2007147185A1 AT 2007000298 W AT2007000298 W AT 2007000298W WO 2007147185 A1 WO2007147185 A1 WO 2007147185A1
Authority
WO
WIPO (PCT)
Prior art keywords
ice
water
added
substance
ppm
Prior art date
Application number
PCT/AT2007/000298
Other languages
German (de)
English (en)
Inventor
Thomas Loerting
Original Assignee
Universität Innsbruck
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universität Innsbruck filed Critical Universität Innsbruck
Priority to US12/306,187 priority Critical patent/US20090301105A1/en
Priority to CA002655336A priority patent/CA2655336A1/fr
Priority to EP07718507A priority patent/EP2041234A1/fr
Publication of WO2007147185A1 publication Critical patent/WO2007147185A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K3/00Materials not provided for elsewhere
    • C09K3/24Materials not provided for elsewhere for simulating ice or snow

Definitions

  • the invention is based on a method for producing an ice surface for an ice rink according to the preamble of claim 1.
  • the ice quality of an ice rink plays in particular in speed competitions such. Speed skating an essential role.
  • the mechanical properties of the ice or the surface of the ice of the ice rinks can be controlled by various parameters, including the ice temperature, the relative humidity and the conductivity of the water forming the ice.
  • the object of the invention is thus to provide a cost-effective method for improving the quality of the ice for ice rinks.
  • the ice forming water is mixed with a substance, the ammonia, an alkali or alkaline earth metal hydroxide, a hydrogen halide, nitric acid, sulfuric acid, phosphoric acid, an alkali, alkaline earth metal ammonium salt of these acids or ammonium bicarbonate or a mixture of several of these substances is.
  • the water is preferably NH 3 , HF, HCl, HBr, HI; NH 4 I, NH 4 F, NH 4 Br, LiOH, NaOH, KOH, Ca (OH) 2 or a mixture of several of these substances added, since these cause the strongest effect of the possible dopants due to their physicochemical properties.
  • the substance added to the water is added in a concentration of up to 5 ppm, which requires only small amounts of the dopants and thus is inexpensive.
  • the maximum concentration of the substance added to the water does not exceed 20 ppm, since this ensures an environmentally friendly concentration which is harmless with regard to contamination by potentially harmful substances.
  • the substance added to the water can be added prior to freezing by admixing with the water in the form of dilute solutions, so that a homogeneous ice layer can be produced.
  • the substance added to the water can be added by treating the ice with liquid containing the additives after freezing, since this also improves the quality of the ice surface produced by undoped water in retrospect during the post-processing of the ice surface can be without having to re-create the ice surface.
  • the method according to the invention provides for selectively adding additives to ice production by freezing deionized water, ie to dope the water. This has the effect that properties such as the coefficient of adhesion or sliding friction or the hardness on the surface can be specifically controlled by these additives.
  • the addition can be done either by admixing with the water in the form of dilute solutions (before freezing) or by treating the ice with a liquid containing the additives (after freezing).
  • An adaptation of the currently used ice making machines is not necessary, since simply water instead of water, such as deionized water, tap water, distilled water, etc., can be used.
  • the doping of the water with 4 ppm NH 3 is described here.
  • a uniform doping with NH 3 can be achieved, for example, by interposing a metering valve which doses a dilute NH 3 solution into the tap water as a function of the flow rate. For example, one liter of a 4% NH 3 solution is added, which is metered in shall be. At a flow rate of 50 liters per minute, the metering valve should meter in 5 milliliters per minute for 200 minutes. This results in a dilution of 1: 10000, so that the tap water ultimately contains 4 ppm NH 3.
  • the ice must be given the time to freeze out homogeneously on the pre-cooled surface. You can use the protocols that Ice Masters currently use. The more time you give the ice, the smaller the cooling rates, the larger the crystals, the smoother the ice surface. Cooling faster, there are small crystals that collide and form interfaces ("triple junctions" or "grain boundaries") - the ice surface is rough.
  • a surface treatment of the ice by means of special ice making machines the method is suitable.
  • These machines which are used in about the 1/3 breaks of ice hockey games, usually have a water tank and a snow container. These machines collect the abraded snow, plan the top layer of ice and apply a new layer of water to the ice. If an appropriate amount of NH 3 is also mixed into the water tank of the machine, previously undoped ice benefits for the first time from the improved surface properties due to the doping or, in the case of ice already produced by doping, the optimized properties of the doped ice remain even after repeated ice-making.
  • 3 ppm HF cause a significant increase in the flow properties of the ice.
  • a skater "cuts" with his skid into the ice and thereby displaces ice from the groove, which normally comes to rest as "snow" on the ice surface.
  • the displaced ice flows much more back into the groove just created, so that firstly less snow comes to rest on the ice surface and secondly the extent of destruction of the ice surface is minimized.
  • the ice surface also gets softer in parallel. If 3 ppm NH 3 is used instead, the opposite effect occurs, the abrasion is intensified, the ice surface is more strongly destroyed and also harder.
  • NH 3 doped ice has a decisive advantage: nowadays Ice Masters adjust the hardness of the ice over the temperature. Soft ice (eg for skaters) are generated by "warm ice” (for example at -3 ° C) makes, during hard ice require that is cooled with a high energy consumption, for example, up to -10 ° C. Using NH 3 doped Ice, so you can produce harder ice even at higher temperatures energy-saving. For organizers of major speed skating events, it is still of great importance that national or continental or even Olympic and world records are run on their tracks. Ice cream, from which one can repel oneself better or on which one glides better, is very important here.
  • the method according to the invention is also suitable for controlling the sliding friction coefficient. So is measurable, that doping causes even cold on a -8O 0 C ice surface a water film which reduces friction. On undoped ice this Wasserhem disappears below about -25 ° C, so that deep-frozen ice is no longer slippery. It would also be conceivable that a dopant is found which greatly increases the sliding friction of ice by suppressing the water flow even at comparatively high temperatures.
  • Good ice surfaces are prepared over a period of several days, as this is the time needed to extract the thermal energy from the water molecules, form crystal nuclei, and achieve optimal crystal growth. Doping with a suitable additive can accelerate all three processes and thus reduce the production time or cost of an ice surface.
  • the investigated substances are incorporated directly into the ice grid up to a concentration of up to 5 ppm and change the formation of so-called D or L defects, the microscopic properties such as relaxation times, H-transfer times, electrical conductivity, etc. This leads to a change in the macroscopic properties.
  • Other substances such as larger inorganic molecules, organic molecules, etc. are not incorporated into the crystal lattice, but only in the lattice cavities or in the grain boundaries, often they are even ejected only over the surface and therefore do not change the microscopic and macroscopic properties of the ice ,
  • the list of substances that can be incorporated into the crystal lattice and are therefore suitable for doping includes ammonia, alkali and alkaline earth hydroxides, hydrogen halides, nitric acid, sulfuric acid, phosphoric acid, alkali metal, alkaline earth and ammonium salts of these acids and ammonium bicarbonate. Particularly preferred are NH 3 (ammonia), HF, HCl, HBr, HI; NH 4 I, NH 4 F, NH 4 Br, LiOH, NaOH, KOH, Ca (OH) 2 or mixtures thereof, which have the greatest potential or effect.
  • the concentration range which must be covered results from the concentration of the molecules directly incorporated (substitutionally) into the lattice and from the minerals already present in the tap water.
  • the limit for fluorides for example, 1.5 ppm, so that for a hard NH 3 doped ice surface first the softening effect of the fluorides must be compensated.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Organic Chemistry (AREA)
  • Materials Applied To Surfaces To Minimize Adherence Of Mist Or Water (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)

Abstract

L'invention concerne un procédé servant à produire une surface de glace pour une piste de patinage par congélation d'eau à laquelle on ajoute une substance inorganique. Le procédé selon l'invention est caractérisé en ce que cette substance inorganique est de l'ammoniac, un hydroxyde alcalin ou alcalino-terreux, un halogénure d'hydrogène, de l'acide nitrique, de l'acide sulfurique, de l'acide phosphorique, un sel alcalin, alcalino-terreux ou d'ammonium de ces acides ou du bicarbonate d'ammonium ou bien un mélange de plusieurs de ces substances.
PCT/AT2007/000298 2006-06-23 2007-06-19 Procédé pour produire une surface de glace pour des pistes de patinage WO2007147185A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/306,187 US20090301105A1 (en) 2006-06-23 2007-06-19 Method for the production of an ice surface for ice rinks
CA002655336A CA2655336A1 (fr) 2006-06-23 2007-06-19 Procede pour produire une surface de glace pour des pistes de patinage
EP07718507A EP2041234A1 (fr) 2006-06-23 2007-06-19 Procédé pour produire une surface de glace pour des pistes de patinage

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ATA1067/2006 2006-06-23
AT0106706A AT503443B1 (de) 2006-06-23 2006-06-23 Verfahren zur herstellung einer eisfläche für eissportbahnen

Publications (1)

Publication Number Publication Date
WO2007147185A1 true WO2007147185A1 (fr) 2007-12-27

Family

ID=38458288

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AT2007/000298 WO2007147185A1 (fr) 2006-06-23 2007-06-19 Procédé pour produire une surface de glace pour des pistes de patinage

Country Status (6)

Country Link
US (1) US20090301105A1 (fr)
EP (1) EP2041234A1 (fr)
AT (1) AT503443B1 (fr)
CA (1) CA2655336A1 (fr)
RU (1) RU2009102028A (fr)
WO (1) WO2007147185A1 (fr)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008072971A1 (fr) * 2006-12-12 2008-06-19 Icemining Technology As Modification de la vitesse d'écoulement de glace industrielle
US8664232B2 (en) 2002-08-21 2014-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US8673927B2 (en) 2006-05-04 2014-03-18 Boehringer Ingelheim International Gmbh Uses of DPP-IV inhibitors
US8846695B2 (en) 2009-01-07 2014-09-30 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
US8853156B2 (en) 2008-08-06 2014-10-07 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US8865729B2 (en) 2008-12-23 2014-10-21 Boehringer Ingelheim International Gmbh Salt forms of a xanthine compound
US8883805B2 (en) 2004-11-05 2014-11-11 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US8962636B2 (en) 2011-07-15 2015-02-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US9149478B2 (en) 2010-06-24 2015-10-06 Boehringer Ingelheim International Gmbh Diabetes therapy
US9155705B2 (en) 2008-04-03 2015-10-13 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US9186392B2 (en) 2010-05-05 2015-11-17 Boehringer Ingelheim International Gmbh Combination therapy
US9266888B2 (en) 2006-05-04 2016-02-23 Boehringer Ingelheim International Gmbh Polymorphs
US9457029B2 (en) 2009-11-27 2016-10-04 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US9486526B2 (en) 2008-08-06 2016-11-08 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US9526730B2 (en) 2012-05-14 2016-12-27 Boehringer Ingelheim International Gmbh Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9713618B2 (en) 2012-05-24 2017-07-25 Boehringer Ingelheim International Gmbh Method for modifying food intake and regulating food preference with a DPP-4 inhibitor
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
US11033552B2 (en) 2006-05-04 2021-06-15 Boehringer Ingelheim International Gmbh DPP IV inhibitor formulations
CN113739470A (zh) * 2021-08-31 2021-12-03 清华大学 冰上运动赛道表层冰面制备方法以及冰上运动赛道
US11911388B2 (en) 2008-10-16 2024-02-27 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014280955B2 (en) * 2014-12-24 2021-07-22 Arctic Ice Project Generation and deployment of ice with modified optical and/or thermal properties
CN113137794A (zh) * 2021-05-21 2021-07-20 松下冷机系统(大连)有限公司 一种速度滑冰场地的二氧化碳制冰管道系统

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE526224C (de) * 1927-01-26 1931-06-06 Edgar Vorwerk Verfahren zur Herstellung einer kuenstlichen Eisbahn
DE19940203A1 (de) * 1999-08-25 2001-03-08 Integral Energietechnik Gmbh Zusatzstoff für ein pumpfähiges Flüssigeisgemisch
RU2005140523A (ru) * 2005-12-26 2006-05-27 Борис Алексеевич Кузнецов (RU) Способ получения двухслойного льда

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361213A (en) * 1965-09-13 1968-01-02 Mobil Oil Corp Method of decreasing friction loss in turbulent liquids
US4953360A (en) * 1989-09-27 1990-09-04 Slick Ice Limited Additive for treating water used to form ice
WO2005077836A1 (fr) * 2004-02-13 2005-08-25 Orca Bay Arena Limited Partnership Procede, appareil et composition permettant de fabriquer de la glace

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE526224C (de) * 1927-01-26 1931-06-06 Edgar Vorwerk Verfahren zur Herstellung einer kuenstlichen Eisbahn
DE19940203A1 (de) * 1999-08-25 2001-03-08 Integral Energietechnik Gmbh Zusatzstoff für ein pumpfähiges Flüssigeisgemisch
RU2005140523A (ru) * 2005-12-26 2006-05-27 Борис Алексеевич Кузнецов (RU) Способ получения двухслойного льда

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE EPODOC EUROPEAN PATENT OFFICE, THE HAGUE, NL; XP002451755 *

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9108964B2 (en) 2002-08-21 2015-08-18 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US8664232B2 (en) 2002-08-21 2014-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US10023574B2 (en) 2002-08-21 2018-07-17 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US9556175B2 (en) 2002-08-21 2017-01-31 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions
US10202383B2 (en) 2002-08-21 2019-02-12 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US9321791B2 (en) 2002-08-21 2016-04-26 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US9751855B2 (en) 2004-11-05 2017-09-05 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US8883805B2 (en) 2004-11-05 2014-11-11 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US9499546B2 (en) 2004-11-05 2016-11-22 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US9266888B2 (en) 2006-05-04 2016-02-23 Boehringer Ingelheim International Gmbh Polymorphs
US9493462B2 (en) 2006-05-04 2016-11-15 Boehringer Ingelheim International Gmbh Polymorphs
US10080754B2 (en) 2006-05-04 2018-09-25 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
US9173859B2 (en) 2006-05-04 2015-11-03 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
US11084819B2 (en) 2006-05-04 2021-08-10 Boehringer Ingelheim International Gmbh Polymorphs
US11033552B2 (en) 2006-05-04 2021-06-15 Boehringer Ingelheim International Gmbh DPP IV inhibitor formulations
US8673927B2 (en) 2006-05-04 2014-03-18 Boehringer Ingelheim International Gmbh Uses of DPP-IV inhibitors
US9815837B2 (en) 2006-05-04 2017-11-14 Boehringer Ingelheim International Gmbh Polymorphs
US10301313B2 (en) 2006-05-04 2019-05-28 Boehringer Ingelheim International Gmbh Polymorphs
US11919903B2 (en) 2006-05-04 2024-03-05 Boehringer Ingelheim International Gmbh Polymorphs
US11291668B2 (en) 2006-05-04 2022-04-05 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
WO2008072971A1 (fr) * 2006-12-12 2008-06-19 Icemining Technology As Modification de la vitesse d'écoulement de glace industrielle
US10022379B2 (en) 2008-04-03 2018-07-17 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US10973827B2 (en) 2008-04-03 2021-04-13 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US9415016B2 (en) 2008-04-03 2016-08-16 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US9155705B2 (en) 2008-04-03 2015-10-13 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US9486526B2 (en) 2008-08-06 2016-11-08 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US8853156B2 (en) 2008-08-06 2014-10-07 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US10034877B2 (en) 2008-08-06 2018-07-31 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US11911388B2 (en) 2008-10-16 2024-02-27 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
US8865729B2 (en) 2008-12-23 2014-10-21 Boehringer Ingelheim International Gmbh Salt forms of a xanthine compound
US9212183B2 (en) 2008-12-23 2015-12-15 Boehringer Ingelheim International Gmbh Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
US8846695B2 (en) 2009-01-07 2014-09-30 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
US10092571B2 (en) 2009-11-27 2018-10-09 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US9457029B2 (en) 2009-11-27 2016-10-04 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US10004747B2 (en) 2010-05-05 2018-06-26 Boehringer Ingelheim International Gmbh Combination therapy
US9603851B2 (en) 2010-05-05 2017-03-28 Boehringer Ingelheim International Gmbh Combination therapy
US9186392B2 (en) 2010-05-05 2015-11-17 Boehringer Ingelheim International Gmbh Combination therapy
US9149478B2 (en) 2010-06-24 2015-10-06 Boehringer Ingelheim International Gmbh Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US11911387B2 (en) 2010-11-15 2024-02-27 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US9199998B2 (en) 2011-07-15 2015-12-01 Boehringer Ingelheim Internatioal Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US8962636B2 (en) 2011-07-15 2015-02-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US10195203B2 (en) 2012-05-14 2019-02-05 Boehringr Ingelheim International GmbH Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US9526730B2 (en) 2012-05-14 2016-12-27 Boehringer Ingelheim International Gmbh Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US9713618B2 (en) 2012-05-24 2017-07-25 Boehringer Ingelheim International Gmbh Method for modifying food intake and regulating food preference with a DPP-4 inhibitor
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
CN113739470A (zh) * 2021-08-31 2021-12-03 清华大学 冰上运动赛道表层冰面制备方法以及冰上运动赛道
CN113739470B (zh) * 2021-08-31 2022-09-09 清华大学 冰上运动赛道表层冰面制备方法以及冰上运动赛道

Also Published As

Publication number Publication date
CA2655336A1 (fr) 2007-12-27
AT503443B1 (de) 2007-10-15
RU2009102028A (ru) 2010-07-27
US20090301105A1 (en) 2009-12-10
EP2041234A1 (fr) 2009-04-01
AT503443A4 (de) 2007-10-15

Similar Documents

Publication Publication Date Title
AT503443B1 (de) Verfahren zur herstellung einer eisfläche für eissportbahnen
AT394199B (de) Gefrierschutz- und eisloesemittel enthaltend polycarbonsaeuren
EP0737169B1 (fr) Composition de traitement d'eau et d'assainissement de sols
DE102010020618B4 (de) Verfahren zur Herstellung von CO2-Pellets oder von CO2-Partikeln mit erhöhter mechanischer Härte und Abrasivität
DE3038152A1 (de) Verfahren zur verhinderung der glatteisbildung auf strassen und zusammensetzung zur durchfuehrung des verfahrens
DE3345648C2 (fr)
DE3014839C2 (de) Verfahren zur Hochtemperatur-Elektrodialyse
AT509864B1 (de) Nukleationsmittel
DE19845490A1 (de) Verfahren zum Schmelzen von Schnee und/oder Eis und ein Enteisungsmittel, enthaltend Natriumformiat und Natriumchlorid
EP1848667B1 (fr) L'utilisation de phosphate de magnésium pour adoucir l'eau
DE19602925C2 (de) Zuschlagstoff für Verkehrsflächen
DE60117986T2 (de) Verfahren zur herstellung von kalziumreichem wasser
DE3141644A1 (de) Umweltfreundliches streusalz und verfahren zu seiner herstellung
DE578716C (de) Verfahren zur Verbesserung von Zement und Zementmoertel
CH331770A (de) Verfahren zur Erhöhung der Schmelzgeschwindigkeit von Schnee und Eis
EP0370358B1 (fr) Procédé pour empêcher la formation de glace ou déglacer les surfaces de roulement et dispositif de mise en oeuvre de ce procédé
AT363962B (de) Verfahren zum bewahren und gegebenenfalls zum herstellen von schneebedeckten flaechen
AT376693B (de) Verfahren zur herstellung von granuliertem streumaterial fuer die bekaempfung der schneeund/oder eisglaette von verkehrsflaechen
DE1594770C3 (de) Verfahren zur Herstellung von Suspensionen von mit bituminösen Stoffen beschichteten Mineralstoffteilchen oder Fasern
DE191302C (fr)
DE2200221B2 (de) Tausalz
EP2948414B1 (fr) Procédé permettant d'éviter la formation de dépôts dans des systèmes de drainage
AT132525B (de) Künstliche Eisbahn.
Schettkat Labour Market Policy in Germany: Fine-Tuning Instead of Blanket Regulation
DE613922C (de) Vorrichtung zur Eiserzeugung durch Teilverdampfung von Wasser im hohen Vakuum

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07718507

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2007718507

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2655336

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2009102028

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12306187

Country of ref document: US